Post Treatment Lyme Study

Join Our Study: Phase 1/2 Clinical Trial

Title:
Randomized, Double-Blind, Placebo-Controlled Trial of Pulse-Dosed Ceftriaxone for Patients with Post-Treatment Lyme Disease Syndrome

Are you or someone you know experiencing persistent symptoms after Lyme disease treatment?

You may be eligible to participate in a groundbreaking clinical trial evaluating a potential new treatment for Post-Treatment Lyme Disease Syndrome (PTLDS).

Study Overview

This Phase 1/2 clinical trial is designed to evaluate the safety and efficacy of pulse-dosed ceftriaxone in patients with Post-Treatment Lyme Disease Syndrome (PTLDS) — a condition where symptoms such as fatigue, joint pain, and neurological issues persist even after standard antibiotic treatment for Lyme disease.

Eligibility Criteria

You may be eligible if you:

Are 18 years or older
Have a confirmed diagnosis of Lyme disease and were treated with appropriate antibiotics
Are experiencing persistent symptoms consistent with Post-Treatment Lyme Disease Syndrome (such as fatigue, joint pain, cognitive dysfunction, etc.)
Are willing to comply with all study protocols and procedures

What the Study Involves

Duration: 12 months
Treatment:

Randomized assignment to either pulse-dosed IV ceftriaxone or a placebo group

Study Visits:

Screening Visit: To determine eligibility
Multiple follow-up visits to monitor your progress and collect data
Regular health assessments and blood tests

Why Participate?

Contribute to important research that could improve treatment options for Post-Treatment Lyme Disease Syndrome
Help advance medical knowledge about Lyme disease and its lingering effects
Receive study related care and health monitoring throughout the study

Interested in Participating?

Please fill out the inquiry form to receive information about this study.

For more information or to see if you qualify, please contact Ms. AlMallah.

Nicole AlMallah
Study Coordinator
201-956-8998
nicole.almallah@hmhn.org

Bindu Balani, M.D.
Principal Investigator
201-487-4088

Hackensack University Medical Center (HUMC)
HMHN David Jurist Research Building
40 Prospect Avenue, Suite 210
Hackensack, NJ 07601

Take action today and help pave the way for better treatments for PTLDS!

This study has been approved by the Institutional Review Board (IRB). Participation is voluntary. All patient information is confidential.